A comparison of calcium to zoledronic acid for improvement of cortical bone in an animal model of CKD

Journal of Bone and Mineral Research

Volumn 29, Issue 4, 2014, Pages 902-910

  Moe, Sharon M ^a,b   Chen, Neal X ^a   Newman, Christopher L ^a   Gattone, Vincent H ^a   Organ, Jason M ^a   Chen, Xianming ^a   Allen, Matthew R ^a  

^a INDIANA UNIVERSITY   (United States)

^b RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

BIOMECHANICS; BONE; CALCIUM; CKD; FGF23; PARATHYROID HORMONE; VASCULAR CALCIFICATION; ZOLEDRONIC ACID

Indexed keywords

CALCIUM; FIBROBLAST GROWTH FACTOR 23; MINERAL; PARATHYROID HORMONE; WATER; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BLOOD VESSEL CALCIFICATION; BONE MASS; BONE REMODELING; CHRONIC KIDNEY DISEASE; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; CORTICAL BONE; DRUG EFFICACY; FOLLOW UP; IMAGING SOFTWARE; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; MALE; MICRO-COMPUTED TOMOGRAPHY; MINERAL APPOSITION RATE; MUSCULOSKELETAL SYSTEM PARAMETERS; NONHUMAN; OSSIFICATION; POROSITY; RAT; RAT MODEL; SECONDARY HYPERPARATHYROIDISM; SINGLE DRUG DOSE; TRABECULAR BONE; UREMIA; ANIMAL; BONE; CARDIOVASCULAR SYSTEM; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; PATHOPHYSIOLOGY; RADIOGRAPHY;

ANIMALS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; CALCIUM; CARDIOVASCULAR SYSTEM; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; IMIDAZOLES; KIDNEY FAILURE, CHRONIC; RATS; X-RAY MICROTOMOGRAPHY;

EID: 84897836177     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2089     Document Type: Article

References (43)

1. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006; 69 (11): 1945-53.
2. Nickolas TL, Leonard MB, Shane E., Chronic kidney disease and bone fracture: a growing concern. Kidney Int. 2008; 74 (6): 721-31.
3. Nickolas T, Stein E, Cohen A, et al. Bone mass and microarchitecture in CKD patients with fracture. J Am Soc Nephrol. 2010 Aug; 21 (8): 1371-80.
4. Lindberg JS, Moe SM., Osteoporosis in end-state renal disease. Semin Nephrol. 1999; 19 (2): 115-22.
5. Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE., Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res. 2005; 20 (12): 2105-15.
6. Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH., Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int. 2007; 18 (1): 59-68.
7. Jamal SA, Bauer DC, Ensrud KE, et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res. 2007; 22 (4): 503-8.
8. KDIGO. Clinical Practice Guidelines for the Management of CKD-MBD. Kidney Int. 2009; 76 (S113): S1-130.
9. Allen MR, Chen NX, Gattone VH 2nd, et al. Skeletal effects of zoledronic acid in an animal model of chronic kidney disease. Osteoporos Int. 2013 Apr; 24 (4): 1471-81.
10. Moe SM, Chen NX, Seifert MF, et al. A rat model of chronic kidney disease-mineral bone disorder. Kidney Int. 2009; 75 (2): 176-84.
11. Moe SM, Radcliffe JS, White KE, et al. The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat. J Bone Miner Res. 2011; 26 (11): 2672-81.
12. Moe SM, Seifert MF, Chen NX, et al. R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD). Nephrol Dial Transplant. 2009 Aug; 24 (8): 2371-7.
13. Marra M, Salzano G, Leonetti C, et al. Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. Nanomedicine. 2011; 7 (6): 955-64.
14. Allen MR, Burr DB., The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg. 2009; 67 (5 Suppl): 61-70.
15. Patntirapong S, Singhatanadgit W, Chanruangvanit C, Lavanrattanakul K, Satravaha Y., Zoledronic acid suppresses mineralization through direct cytotoxicity and osteoblast differentiation inhibition. J Oral Pathol Med. 2012; 41 (9): 713-20.
16. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2 (6): 595-610.
17. Nickolas TL, Cremers S, Zhang A, et al. Discriminants of prevalent fractures in chronic kidney disease. J Am Soc Nephrol. 2011; 22 (8): 1560-72.
18. Ensrud KE, Lui LY, Taylor BC, et al. Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med. 2007; 167 (2): 133-9.
19. Barreto DV, Barreto Fde C, de Carvalho AB, et al. Phosphate binder impact on bone remodeling and coronary calcification-results from the BRiC study. Nephron Clin Pract. 2008; 110 (4): c273-83.
20. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356 (18): 1809-22.
21. Brown JE, Ellis SP, Lester JE, et al. Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid. Clin Cancer Res. 2007; 13 (18 Pt 1): 5406-10.
22. Calis KA, Pucino F., Zoledronic acid and secondary prevention of fractures. N Engl J Med. 2007; 357 (18): 1861-2.
23. Bischoff-Ferrari HA, Dawson-Hughes B, Baron JA, et al. Calcium intake and hip fracture risk in men and women: a meta-analysis of prospective cohort studies and randomized controlled trials. Am J Clin Nutr. 2007; 86 (6): 1780-90.
24. Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction,cardiovascular events: meta-analysis. BMJ. 2010; 341: c3691.
25. Parfitt AM., The hyperparathyroidism of chronic renal failure: a disorder of growth. Kidney Int. 1997; 52 (1): 3-9.
26. Parfitt AM., Misconceptions (2): turnover is always higher in cancellous than in cortical bone. Bone. 2002; 30 (6): 807-9.
27. Sprague SM, Moe SM., The case for routine parathyroid hormone monitoring. Clin J Am Soc Nephrol. 2013 Feb; 8 (2): 313-8.
28. Leonard MB., A structural approach to skeletal fragility in chronic kidney disease. Semin Nephrol. 2009; 29 (2): 133-43.
29. EVOLVE Trial Investigators, Chertow GM, Block GA, Correa-Rotter R., Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367 (26): 2482-94.
30. Tamura K, Suzuki Y, Matsushita M, Fujii H, Miyaura C, Aizawa S, Kogo H., Prevention of aortic calcification by etidronate in the renal failure rat model. Eur J Pharmacol 2007 558 (1-3): 159-66.
31. Price PA, Faus SA, Williamson MK., Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol. 2001; 21 (5): 817-24.
32. Lomashvili KA, Monier-Faugere MC, Wang X, Malluche HH, O'Neill WC., Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int. 2009 Mar; 75 (6): 617-25.
33. Touchberry CD, Green TM, Tchikrizov V, et al. FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. Am J Physiol Endocrinol Metab. 2013; 304 (8): E863-73.
34. Moe SM., Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. Eur J Clin Invest. 2006; 36 (Suppl 2): 51-62.
35. Kurz P, Monier-Faugere MC, Bognar B, et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int. 1994; 46 (3): 855-61.
36. Hill KM, Martin BR, Wastney ME, et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int. 2013 May; 83 (5): 959-66.
37. Rodriguez-Ortiz ME, Lopez I, Munoz-Castaneda JR, et al. Calcium deficiency reduces circulating levels of FGF23. J Am Soc Nephrol. 2012; 23 (7): 1190-7.
38. Lim K, Lu TS, Molostvov G, et al. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation. 2012; 125 (18): 2243-55.
39. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011; 121 (11): 4393-408.
40. Nitta K, Akiba T, Suzuki K, et al. Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis. 2004; 44 (4): 680-8.
41. Hashiba H, Aizawa S, Tamura K, Shigematsu T, Kogo H., Inhibitory effects of etidronate on the progression of vascular calcification in hemodialysis patients. Ther Apher Dial. 2004; 8 (3): 241-7.
42. Quinn SJ, Thomsen AR, Pang JL, et al. Interactions between calcium and phosphorus in the regulation of the production of fibroblast growth factor 23 in vivo. Am J Physiol Endocrinol Metab. 2013; 304 (3): E310-20.
43. Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG., Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis. 2010; 56 (1): 57-68.